Oruka Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Oruka Therapeutics, Inc. (ORKA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $27.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Oruka Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $27.40M.
- Oruka Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was $1.10M, a 42.11% decline from fiscal 2018.
- Oruka Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2018 was $1.90M.
- Oruka Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was -$13.20M, a 312.90% decline from fiscal 2016.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 11 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 11 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|
| 2025-12-31 | $27.40M 10-K · filed 2026-03-12 | ||
| 2024-12-31 | $21.32M 10-K · filed 2026-03-12 | ||
| 2019-12-31 | $1.10M 10-K · filed 2020-02-18 | ||
| 2018-12-31 | $1.90M 10-K · filed 2019-02-27 | ||
| 2017-12-31 | -$13.20M 10-K · filed 2018-03-22 | ||
| 2016-12-31 | $6.20M 10-K · filed 2017-03-21 | ||
| 2015-12-31 | $4.20M 10-K · filed 2016-03-17 | ||
| 2014-12-31 | -$400.00K 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |